HALEON stock snapshot.
Haleon Pakistan Limited price, fundamentals, financial report trends, and one-year performance against the KSE-100.
HALEON vs. KSE-100
Latest report-period signals.
Parsed conservatively from PSX financial report PDFs. Card values are latest report-period figures, so quarterly filings show quarterly values rather than annualized totals.
Report metrics extracted
| Stock | Trailing P/E | Price / book | ROE | Net margin | Debt / equity | Market cap | Day change |
|---|---|---|---|---|---|---|---|
HALEON Haleon Pakistan Limited | 13.82 | 6.05 | 43.07% | 14.78% | 105.49% | PKR 88.1bn | -0.15% |
| GLAXO →GlaxoSmithKline Pakistan Limited | 10.98 | 3.03 | 29.77% | 15.21% | 48.79% | PKR 110.1bn | -0.21% |
| ABOT →Abbott Laboratories (Pakistan) Limited | 11.27 | 2.67 | 25.19% | 10.57% | 48.93% | PKR 89.8bn | +0.36% |
| AGP →AGP Limited | 22.65 | 3.97 | 18.27% | 11.49% | 62.09% | PKR 53.5bn | -0.20% |
| SEARL →The Searle Company Limited | n/a | 1.38 | 7.97% | -4.89% | 45.25% | PKR 52.8bn | -0.47% |
Haleon Pakistan Limited
Haleon Pakistan Limited (formerly known as GlaxoSmithKline Consumer Healthcare Pakistan Limited) was incorporated in Pakistan as a public listed company under the provisions of the repealed Companies Ordinance, 1984 (now Companies Act, 2017) on 31 March 2015. The Company is a subsidiary of ‘Haleon Netherlands B.V’. The ultimate parent of the Company is Haleon plc. The Company is inter alia principally engaged in the manufacturing, marketing and sale of consumer healthcare and over the counter health products.
Turn HALEON from a quote into a decision trail.
PSX Clarity connects live prices, filings, dividends, and report metrics to the portfolio you actually follow.